Contact
searchSearch
HMP Global
Login

EGFR Videos

Benjamin Besse, MD, PhD
Conference Coverage
First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
10/21/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/21/2024
Oncology
Suresh Ramalingam, MD
Conference Coverage
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
06/02/2024
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology
Natasha Leighl, MD
Conference Coverage
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
06/01/2024
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023
Nicolas Girard, MD
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
Roy Herbst, MD, PhD, Yale Cancer Center
Videos
Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC
06/19/2023
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
Joshua Sabari, MD, NYU Langone Health, New York, NY
Videos
Mortality on Osimertinib for Patients With EGFR-Mutant NSCLC
05/30/2023
Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.
Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.
Joshua Sabari, MD, NYU Langone...
05/30/2023
Oncology
Heather Wakelee, MD, Stanford University, Palo Alto, California
Videos
Frontline Treatment Options for Patients With EGFR-Mutated NSCLC
05/18/2023
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses...
05/18/2023
Oncology
Helena Yu, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Videos
Combating Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Cancer
05/17/2023
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and...
05/17/2023
Oncology
Helena Yu, MD
Videos
EGFR TKIs for Curative Intent Among Patients With Early-Stage Non-Small Cell Lung Cancer
11/15/2022
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the...
11/15/2022
Oncology
Helena Yu, MD
Videos
EGFR: First Line, Second Line and Beyond in the Age of Osimertinib
11/07/2022
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting...
11/07/2022
Oncology

Recent News

News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
News
Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer
09/12/2025
Stephanie Holland
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy...
09/12/2025
Oncology
News
Durvalumab Plus Platinum-Based Chemotherapy for Treatment-Naive Patients With Extensive-Stage Small Cell Lung Cancer
09/10/2025
Stephanie Holland
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory...
09/10/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
FDA Approval
FDA Approves Selumetinib Granules and Capsules for Pediatric Patients With NF1-Associated Symptomatic and Inoperable Plexiform Neurofibromas
09/10/2025
Stephanie Holland
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib...
09/10/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
News
Dual Immune Checkpoint Blockade Plus Radiotherapy Fails to Improve Outcomes Among Newly Diagnosed Patients With MGMT-Unmethylated Glioblastoma
08/28/2025
Stephanie Holland
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a...
08/28/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use